Schering-Plough to develop Centocor arthritis treatment

Johnson & Johnson biotech subsidiary Centocor won backing from Schering-Plough on its developmental treatment for rheumatoid arthritis. In exercising previously acquired rights to jointly develop the drug, a monoclonal antibody, Schering-Plough is taking on $125 million in Centocor's previous R&D costs and will share future costs of getting the drug to market. In exchange, Schering-Plough will get some exclusive marketing rights, similar to its deal with Centocor on Remicade.

- read this AP story for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.